PURA CBD First Acquisition In Rollup Campaign Scheduled To Close On Thursday
February 24 2020 - 1:25PM
InvestorsHub NewsWire
Dallas, TX -- February 24, 2020 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced plans to close the acquisition of a CBD
Infused Pet Products operation on Thursday this week, February
27th. PURA plans to acquire the CBD Infused Pet Products in
exchange for an ongoing royalty payment. PURA has also
committed to funding the CBD Infused Pet Products marketing
launch. The CBD pet products market is anticipated to
reach $1.16
billion in the U.S. alone
by 2022. The seller
currently provides concierge pet services through a mobile app
portal and already has a thriving client base anticipated to help
accelerate the sales growth of the CBD Infused Pet Products under
the PURA umbrella.
PURA recently launched a campaign to
acquire CBD infused beverage, edible and topical operations and
also announced closing on a $5 million investment to fund the
acquisition campaign. The $5 million investment is structured as a
debt facility whereby funds can be drawn as needed to fund
acquisitions. The drawn funds would be secured by the
acquired asset and the debt can be repaid in stock at $0.10 per
share. The CBD Infused Pet Products acquisition schedule this
Thursday is the first in an anticipated series of
acquisitions. PURA is currently working to finalize the
acquisition of a CBD Infused Confections operation and working to
build a pipeline of more acquisition
opportunities.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024